Christopher A Hunter Selected Research

Toxoplasmosis

1/2021	Limited Impact of the Inhibitory Receptor TIGIT on NK and T Cell Responses during Toxoplasma gondii Infection.
12/2019	Impact of Interleukin-27p28 on T and B Cell Responses during Toxoplasmosis.
11/2019	Caspase-8 promotes c-Rel-dependent inflammatory cytokine expression and resistance against Toxoplasma gondii.
11/2015	Flt3 Ligand Is Essential for Survival and Protective Immune Responses during Toxoplasmosis.
10/2014	Use of transgenic parasites and host reporters to dissect events that promote interleukin-12 production during toxoplasmosis.
2/2014	The aryl hydrocarbon receptor promotes IL-10 production by NK cells.
1/2013	A host GPCR signaling network required for the cytolysis of infected cells facilitates release of apicomplexan parasites.
1/2013	IL-21 is required for optimal antibody production and T cell responses during chronic Toxoplasma gondii infection.
9/2012	Cutting edge: suppression of GM-CSF expression in murine and human T cells by IL-27.
9/2011	A critical role for SOCS3 in innate resistance to Toxoplasma gondii.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher A Hunter Research Topics

Disease

75	Infections 01/2022 - 03/2002
27	Inflammation (Inflammations) 10/2021 - 10/2002
21	Toxoplasmosis 01/2021 - 03/2002
8	Neoplasms (Cancer) 10/2019 - 02/2003
5	Persistent Infection 07/2015 - 10/2002
4	Encephalitis (Encephalitis, Rasmussen) 01/2019 - 08/2005
3	Parasitic Diseases (Parasitic Disease) 11/2021 - 10/2004
3	Colitis 01/2019 - 06/2008
3	Malaria 01/2013 - 08/2010
2	Cryptosporidiosis 12/2021 - 10/2019
2	COVID-19 10/2021 - 01/2021
2	Neurodegenerative Diseases (Neurodegenerative Disease) 07/2021 - 02/2020
2	Fibrosis (Cirrhosis) 01/2020 - 12/2014
2	Dysbiosis 01/2019 - 01/2019
2	Multiple Sclerosis 01/2019 - 05/2006
2	Crohn Disease (Crohn's Disease) 01/2019 - 06/2008
2	Leishmaniasis 01/2016 - 10/2009
2	Vitiligo 04/2015 - 02/2014
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 09/2012 - 05/2009
2	Autoimmune Diseases (Autoimmune Disease) 05/2009 - 05/2006
1	Ischemia 11/2022
1	Anemia 10/2021
1	Viral Pneumonia 10/2021
1	Pneumonia (Pneumonitis) 10/2021
1	Sepsis (Septicemia) 10/2021
1	Parkinson Disease (Parkinson's Disease) 07/2021
1	Ureteral Obstruction 01/2020
1	Cytokine Release Syndrome 01/2020
1	Chronic Renal Insufficiency 01/2020
1	Bacterial Infections (Bacterial Infection) 11/2019
1	Necrosis 11/2019
1	Pediatric Crohn's disease 01/2019
1	Foodborne Diseases 01/2019
1	Paramyxoviridae Infections (Parainfluenza) 01/2017
1	Dengue (Dengue Fever) 01/2017
1	Zika Virus Infection 01/2017
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2016

Drug/Important Bio-Agent (IBA)

40	CytokinesIBA 11/2022 - 04/2002
27	Interleukin-27 (Interleukin 27)IBA 11/2021 - 01/2004
21	Interleukin-12 (IL 12)IBA 11/2019 - 04/2002
13	Interleukin-10 (Interleukin 10)IBA 01/2021 - 04/2002
11	AntigensIBA 01/2022 - 12/2004
10	Proteins (Proteins, Gene)FDA Link 07/2021 - 07/2002
10	Interleukin-17 (Interleukin 17)IBA 01/2020 - 07/2005
7	Transcription Factors (Transcription Factor)IBA 01/2020 - 07/2002
6	Interferon-gamma (Interferon, gamma)IBA 01/2019 - 09/2002
6	NF-kappa B (NF-kB)IBA 08/2005 - 05/2002
5	InterferonsIBA 01/2022 - 09/2012
5	Interleukin-23 (Interleukin 23)IBA 06/2008 - 08/2004
4	LigandsIBA 07/2021 - 05/2013
4	Interleukin-6 (Interleukin 6)IBA 01/2021 - 02/2010
3	Interleukin-18 (Interleukin 18)IBA 12/2021 - 01/2003
3	Messenger RNA (mRNA)IBA 01/2020 - 09/2002
3	InterleukinsIBA 12/2014 - 04/2006
3	Interleukin-12 Subunit p40IBA 05/2013 - 03/2002
3	Interleukin-2 (IL2)IBA 01/2013 - 09/2002
3	Interleukin-13IBA 04/2006 - 10/2002
2	InflammasomesIBA 12/2021 - 11/2019
2	SynucleinsIBA 07/2021 - 01/2019
2	ChemokinesIBA 01/2020 - 06/2012
2	Phosphotransferases (Kinase)IBA 01/2020 - 06/2013
2	CollagenIBA 01/2020 - 12/2014
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2019 - 11/2003
2	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2019 - 01/2014
2	EnzymesIBA 01/2019 - 12/2009
2	AntibodiesIBA 01/2017 - 05/2006
2	Chemokine CXCL10IBA 04/2015 - 02/2014
2	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2015 - 07/2013
2	VaccinesIBA 04/2012 - 08/2010
2	Arachidonate 15-Lipoxygenase (Arachidonate 15 Lipoxygenase)IBA 12/2009 - 09/2002
2	Interleukin-5 (Interleukin 5)IBA 04/2006 - 01/2005
2	Interleukin-4 (Interleukin 4)IBA 01/2005 - 04/2004
1	Chemotactic FactorsIBA 11/2022
1	Mitochondrial DNA (mtDNA)IBA 10/2021
1	DNA (Deoxyribonucleic Acid)IBA 10/2021
1	Amyloid (Amyloid Fibrils)IBA 07/2021
1	Indicators and Reagents (Reagents)IBA 07/2021
1	Caspase 8 (Caspase-8)IBA 11/2019
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2019
1	CarbocyaninesIBA 10/2019
1	Deoxyglucose (2 Deoxy D glucose)IBA 10/2019
1	Coloring Agents (Dyes)IBA 10/2019
1	EstersIBA 10/2019
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 10/2019
1	Bile Acids and Salts (Bile Acids)IBA 01/2019
1	AnionsIBA 01/2019
1	Deoxycholic Acid (Sodium Deoxycholate)IBA 01/2019
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2019
1	NitratesIBA 01/2019
1	Interferon Regulatory FactorsIBA 01/2018
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2017
1	NucleosidesIBA 01/2017
1	nanchangmycinIBA 01/2017
1	Interleukin-3 Receptors (Interleukin 3 Receptor)IBA 10/2016
1	blinatumomabIBA 10/2016

Therapy/Procedure

8	Therapeutics 01/2021 - 05/2006
2	Ligation 06/2005 - 07/2004
1	Intravenous Injections 10/2019
1	Diet Therapy (Therapy, Diet) 01/2019
1	Enteral Nutrition (Feeding, Tube) 01/2019